A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA